BTIG Research Lowers Billiontoone (NASDAQ:BLLN) Price Target to $130.00

Billiontoone (NASDAQ:BLLN) had its target price lowered by research analysts at BTIG Research from $142.00 to $130.00 in a note issued to investors on Thursday,Benzinga reports. The firm presently has a “buy” rating on the stock. BTIG Research’s price target suggests a potential upside of 39.20% from the company’s current price.

A number of other analysts have also weighed in on BLLN. Weiss Ratings raised Billiontoone from a “sell (d)” rating to a “sell (d+)” rating in a research note on Tuesday, June 23rd. Guggenheim assumed coverage on shares of Billiontoone in a report on Monday, June 29th. They set a “buy” rating and a $125.00 price target for the company. Finally, JPMorgan Chase & Co. increased their price target on shares of Billiontoone from $120.00 to $125.00 and gave the company an “overweight” rating in a research report on Thursday, May 7th. Six equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $126.71.

Billiontoone Stock Up 1.9%

BLLN opened at $93.39 on Thursday. Billiontoone has a 12 month low of $61.96 and a 12 month high of $150.44. The company has a current ratio of 11.69, a quick ratio of 10.58 and a debt-to-equity ratio of 0.17. The business’s 50-day moving average price is $116.49 and its 200-day moving average price is $94.28. The company has a market cap of $4.30 billion and a P/E ratio of 133.41.

Billiontoone (NASDAQ:BLLN) last posted its quarterly earnings results on Wednesday, August 5th. The company reported $0.15 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.15. The business had revenue of $109.45 million for the quarter. Billiontoone had a return on equity of 9.96% and a net margin of 8.04%. On average, equities analysts expect that Billiontoone will post 0.92 EPS for the current year.

Insiders Place Their Bets

In related news, insider Shan Riku Sakakibara sold 8,000 shares of the firm’s stock in a transaction on Wednesday, June 24th. The stock was sold at an average price of $110.00, for a total value of $880,000.00. Following the completion of the sale, the insider owned 208,000 shares of the company’s stock, valued at $22,880,000. This trade represents a 3.70% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CTO David Tsao sold 20,000 shares of Billiontoone stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $102.27, for a total value of $2,045,400.00. Following the sale, the chief technology officer directly owned 1,000 shares in the company, valued at approximately $102,270. The trade was a 95.24% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 202,049 shares of company stock worth $23,496,861 in the last ninety days. Insiders own 50.22% of the company’s stock.

Institutional Investors Weigh In On Billiontoone

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Rossby Financial LCC purchased a new position in Billiontoone during the fourth quarter valued at $25,000. Wells Fargo & Company MN purchased a new stake in shares of Billiontoone in the 4th quarter worth about $76,000. Smartleaf Asset Management LLC bought a new position in shares of Billiontoone in the 4th quarter worth about $80,000. Nano Cap New Millennium Growth Fund L P bought a new position in shares of Billiontoone in the 4th quarter worth about $82,000. Finally, Renaissance Capital LLC purchased a new position in Billiontoone during the 4th quarter valued at about $201,000.

Billiontoone Company Profile

BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.